NEUROCRINE BIOSCIENCES INC's ticker is and the CUSIP is 64125CAD1. A total of 45 filers reported holding NEUROCRINE BIOSCIENCES INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $18,023 | +3.1% | 10,000 | 0.0% | 0.00% | – |
| Q4 2023 | $17,485 | +17.1% | 10,000 | 0.0% | 0.00% | – |
| Q3 2023 | $14,930 | +17.3% | 10,000 | 0.0% | 0.00% | – |
| Q2 2023 | $12,725 | -5.1% | 10,000 | 0.0% | 0.00% | – |
| Q1 2023 | $13,415 | -22.8% | 10,000 | -9.1% | 0.00% | – |
| Q4 2022 | $17,367 | +2.2% | 11,000 | -8.3% | 0.00% | – |
| Q3 2022 | $17,000 | +88.9% | 12,000 | +71.4% | 0.00% | – |
| Q2 2022 | $9,000 | 0.0% | 7,000 | 0.0% | 0.00% | – |
| Q1 2022 | $9,000 | +12.5% | 7,000 | 0.0% | 0.00% | – |
| Q4 2021 | $8,000 | -11.1% | 7,000 | 0.0% | 0.00% | – |
| Q3 2021 | $9,000 | 0.0% | 7,000 | 0.0% | 0.00% | – |
| Q2 2021 | $9,000 | 0.0% | 7,000 | 0.0% | 0.00% | – |
| Q1 2021 | $9,000 | 0.0% | 7,000 | 0.0% | 0.00% | – |
| Q4 2020 | $9,000 | +800.0% | 7,000 | +600.0% | 0.00% | – |
| Q3 2020 | $1,000 | -50.0% | 1,000 | 0.0% | 0.00% | – |
| Q2 2020 | $2,000 | +100.0% | 1,000 | 0.0% | 0.00% | – |
| Q1 2020 | $1,000 | – | 1,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SSI INVESTMENT MANAGEMENT LLC | 7,440,000 | $10,058,000 | 0.84% |
| SHENKMAN CAPITAL MANAGEMENT INC | 4,121,000 | $5,579,000 | 0.72% |
| Baker Brothers Advisors | 53,270,000 | $71,994,000 | 0.46% |
| LINDEN ADVISORS LP | 11,675,000 | $15,814,000 | 0.36% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 11,558,000 | $15,650,000 | 0.34% |
| AQR Arbitrage LLC | 20,000,000 | $27,077,000 | 0.34% |
| CSS LLC/IL | 3,455,000 | $4,675,000 | 0.28% |
| RWC Asset Management LLP | 4,000,000 | $5,396,000 | 0.25% |
| MACKAY SHIELDS LLC | 21,460,000 | $29,043,000 | 0.21% |
| Calamos Advisors LLC | 24,105,000 | $32,660,000 | 0.20% |